AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31550872 — intervention group
Group type: COMPARATOR
Intervention: Propofol and remifentanil (Group R)
Number of subjects: 90
Study 31550872 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of test conditions (Group K)
Number of subjects: 90
Study 28480522 — intervention group
Group type: EXPERIMENTAL
Intervention: Velcro ties
Number of subjects: 63
Study 28480522 — intervention group
Group type: COMPARATOR
Intervention: Twill ties
Number of subjects: 63
Study 26202655 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI classification
Number of subjects: 106
Study 26202655 — intervention group
Group type: EXPERIMENTAL
Intervention: GUSTO classification
Number of subjects: 106
Study 26202655 — intervention group
Group type: EXPERIMENTAL
Intervention: PLATO classification
Number of subjects: 106
Study 26202655 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC classification
Number of subjects: 106
Study 26202655 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bleeding complications
Number of subjects: 106
Study 26202655 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with hemodynamic status
Number of subjects: 106
Study 24121064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 50
Study 24121064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22197958 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-visor cap
Number of subjects: 11
Study 22197958 — intervention group
Group type: COMPARATOR
Intervention: Nonvisor cap
Number of subjects: 11
Study 19497944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive home visiting (n=67)
Number of subjects: 131
Study 19497944 — intervention group
Group type: COMPARATOR
Intervention: Standard services (n=64)
Number of subjects: 131
Study 16129623 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with a history of low-back injury (HxLBI)
Number of subjects: 242
Study 16129623 — intervention group
Group type: COMPARATOR
Intervention: Athletes without a history of low-back injury (No HxLBI)
Number of subjects: 242
Study 16129623 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with first-time injury
Number of subjects: 242
Study 16129623 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with single and multiple episode low-back injury
Number of subjects: 242
Study 16129623 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with short and long symptom duration
Number of subjects: 242
Study 12860492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-disintegrating oral risperidone tablet (0.5 mg)
Number of subjects: 37
Study 12860492 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral risperidone tablet (0.5 mg)
Number of subjects: 37
Study 12860492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (fast-disintegrating and conventional)
Number of subjects: 37
Study 10530501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Quinone Q10 (100 mg) with Bio‐Antox (n = 13, group 2)
Number of subjects: 24
Study 10530501 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Antox (n = 11, group 1)
Number of subjects: 24
Study 8656146 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole 10 mg every 12th h
Number of subjects: 94
Study 8656146 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil 100 mg every 12th h
Number of subjects: 94
Study 8656146 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole 10 mg every 8th h
Number of subjects: 94
Study 8656146 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil 100 mg every 8th h
Number of subjects: 94
Study 8656146 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole 10 mg every 6th h
Number of subjects: 94
Study 8656146 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil 100 mg every 6th h
Number of subjects: 94
Study 2068543 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 44
Study 2068543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6509781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of T3 therapy (20 micrograms twice a day)
Number of subjects: 4
Study 6509781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30902696 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐US‐PCNL
Number of subjects: 392
Study 30902696 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐US‐PCNL
Number of subjects: 392
Study 30902696 — intervention group
Group type: COMPARATOR
Intervention: C‐PCNL
Number of subjects: 392
Study 30286714 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Fitness Programme
Number of subjects: 17
Study 26783736 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-based home telehealth program
Number of subjects: 178
Study 26783736 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study 25179973 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + mitral valve repair
Number of subjects: 84
Study 25179973 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 84
Study 22279559 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger Tapping Test in Virtual Reality (FT(VR))
Number of subjects: 3
Study 22279559 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger Tapping Test in Real World (FT(REAL))
Number of subjects: 3
Study 22279559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-class correlation coefficients (ICC) for FT(VR)
Number of subjects: 3
Study 22279559 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of FT(VR) vs FT(REAL)
Number of subjects: 3
Study 20807892 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly bortezomib
Number of subjects: 511
Study 20807892 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly bortezomib
Number of subjects: 511
Study 17674763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine
Number of subjects: 177
Study 17674763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 177
Study 17674763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 16342083 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercises
Number of subjects: 140
Study 16342083 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise and pulse ultrasound for periarticular soft tissue pain
Number of subjects: 140
Study 16342083 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise, pulse ultrasound, and intraarticular hyaluronan therapy
Number of subjects: 140
Study 16342083 — intervention group
Group type: COMPARATOR
Intervention: Control group (group IV)
Number of subjects: 140
Study 12476504 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch compression bandaging
Number of subjects: 65
Study 10400483 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 256
Study 10400483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 256
Study 10400483 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin intolerance
Number of subjects: 256
Study 10400483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaphylactoid reactions induced by NSAIDs
Number of subjects: 256
Study 10400483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazolones
Number of subjects: 256
Study 7759787 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.04 mg/m2 body surface twice daily for 12 months)
Number of subjects: 12
Study 7759787 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine withdrawal (P2)
Number of subjects: 12
Study 7759787 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine reinstatement (P3)
Number of subjects: 12
Study 7759787 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (P1)
Number of subjects: 12
Study 2676257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 420000
Study 2676257 — intervention group
Group type: COMPARATOR
Intervention: Prolonged difference in usual DBP of approximately 6 mmHg
Number of subjects: 420000
Study 321182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine dental gel
Number of subjects: 117
Study 321182 — intervention group
Group type: COMPARATOR
Intervention: Placebo quinine sulfate-containing gel
Number of subjects: 117
Study 26951059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Number of subjects: 98
Study 26951059 — intervention group
Group type: COMPARATOR
Intervention: Paying Attention in Class
Number of subjects: 98
Study 30203005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study 30203005 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering
Number of subjects: 0
Study 27068999 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback reports provided through a web-based application with performance scores and benchmark comparisons.
Number of subjects: 41
Study 27068999 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance being benchmarked as low and intermediate.
Number of subjects: 41
Study 25770117 — intervention group
Group type: EXPERIMENTAL
Intervention: pCMV-vegf165 intramuscular injections (1.2 mg, 2 injections, 14 days apart) with standard pharmacological treatment
Number of subjects: 100
Study 25770117 — intervention group
Group type: EXPERIMENTAL
Intervention: pCMV-vegf165 intramuscular injections
Number of subjects: 100
Study 25770117 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 100
Study 24187867 — intervention group
Group type: EXPERIMENTAL
Intervention: Yang‐warming and kidney essence‐replenishing herbal paste
Number of subjects: 151
Study 24187867 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment according to the Global Initiative for Asthma scheme
Number of subjects: 151
Study 21217436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical intervertebral fusion cage (CIFC)
Number of subjects: 73
Study 21217436 — intervention group
Group type: COMPARATOR
Intervention: Cloward procedure (CP)
Number of subjects: 73
Study 18377900 — intervention group
Group type: EXPERIMENTAL
Intervention: Insemination media with higher nitric oxide metabolite levels
Number of subjects: 11
Study 18377900 — intervention group
Group type: COMPARATOR
Intervention: Morphological predictors
Number of subjects: 11
Study 17576863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse steroids in addition to standard intravenous immunoglobulin
Number of subjects: 190
Study 15547572 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive sexually transmitted disease curriculum (2-hour laboratory module, lectures, syllabus, pretest/posttest)
Number of subjects: 108
Study 15547572 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending sexually transmitted disease clinic (n = 47)
Number of subjects: 108
Study 15547572 — intervention group
Group type: COMPARATOR
Intervention: No sexually transmitted disease clinic (n = 61)
Number of subjects: 108
Study 11267855 — intervention group
Group type: EXPERIMENTAL
Intervention: Women informed about normal or benign results at the recall clinic
Number of subjects: 509
Study 11267855 — intervention group
Group type: COMPARATOR
Intervention: Women referred to surgical biopsy
Number of subjects: 509
Study 9384010 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated professional development participants
Number of subjects: 41
Study 9384010 — intervention group
Group type: COMPARATOR
Intervention: Peer consultation participants
Number of subjects: 41
Study 8174140 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed AMI
Number of subjects: 3
Study 8174140 — intervention group
Group type: COMPARATOR
Intervention: Possible AMI
Number of subjects: 3
Study 8174140 — intervention group
Group type: COMPARATOR
Intervention: Definitely ruled out AMI
Number of subjects: 3
Study 2607058 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg, 10 mg, 15 mg, and 20 mg
Number of subjects: 45
Study 2607058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1110481 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 per cent dextrose in normal saline infusions
Number of subjects: 400
Study 1110481 — intervention group
Group type: COMPARATOR
Intervention: 5 per cent dextrose in water
Number of subjects: 400
Study 31015560 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (verbal suggestion that treatment was effective)
Number of subjects: 30
Study 31015560 — intervention group
Group type: COMPARATOR
Intervention: Control group (told that treatment was inert)
Number of subjects: 30
Study 27896858 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir + sofosbuvir + ribavirin (12 weeks)
Number of subjects: 46
Study 27896858 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir + sofosbuvir (12 weeks)
Number of subjects: 46
Study 27896858 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir + sofosbuvir (24 weeks)
Number of subjects: 46
Study 27896858 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir + sofosbuvir (with or without ribavirin)
Number of subjects: 46
Study 26397029 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporesction with a 2 μm CW thulium laser (LVRBT)
Number of subjects: 292
Study 26397029 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection with a bipolar electrocautery system (TURBT)
Number of subjects: 292
Study 23590978 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TBR neurofeedback (NF)
Number of subjects: 180
Study 23590978 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback (NF)
Number of subjects: 180
Study 21750358 — intervention group
Group type: EXPERIMENTAL
Intervention: HiToP (High Tone Power Therapy)
Number of subjects: 68
Study 21750358 — intervention group
Group type: COMPARATOR
Intervention: Mock HiToP (placebo)
Number of subjects: 68
Study 18853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D(3) twice daily)
Number of subjects: 36282
Study 18853250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 18853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 36282
Study 18853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D(3) daily)
Number of subjects: 36282
Study 23285154 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral doxycycline twice a day for 30 days
Number of subjects: 98
Study 23285154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 16019766 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (local surface anesthesia)
Number of subjects: 80
Study 16019766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prilocaine (periprosthetic nerve blockade)
Number of subjects: 80
Study 16019766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (periprosthetic nerve blockade)
Number of subjects: 80
Study 16019766 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (control)
Number of subjects: 80
Study 12718836 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK MMR vaccine (three lots), 125 subjects each lot
Number of subjects: 500
Study 12718836 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK MMR vaccine
Number of subjects: 500
Study 12718836 — intervention group
Group type: COMPARATOR
Intervention: Merck MMR vaccine, 125 subjects
Number of subjects: 500
Study 12718836 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK MMR vaccine and Merck MMR vaccine
Number of subjects: 500
Study 9449500 — intervention group
Group type: EXPERIMENTAL
Intervention: Active challenge with a single-dose drink equivalent to 300 ml of cow's milk
Number of subjects: 20
Study 9449500 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 20
Study 9449500 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (cow's milk)
Number of subjects: 20
Study 9449500 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 9449500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and placebo treatments
Number of subjects: 20
Study 8595072 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ibuprofen gel (500 mg, 10 g 5% gel on the back, area of 20 x 20 cm) with occlusion for 2 h
Number of subjects: 18
Study 8595072 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen tablet (400 mg)
Number of subjects: 18
Study 2226879 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute thrombectomy combined with a temporary arterio‐venous fistula (AVF) and anti‐coagulation
Number of subjects: 41
Study 2226879 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation
Number of subjects: 41
Study 389050 — intervention group
Group type: EXPERIMENTAL
Intervention: LRH (Luteinizing Hormone-Releasing Hormone)
Number of subjects: 13
Study 389050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11811223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg (max 5mg/dose) plus MgO for 4 weeks
Number of subjects: 84
Study 11811223 — intervention group
Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) alone (125 mg three times a day for <20 kg or 250 mg three times a day for >20 kg)
Number of subjects: 84
Study 11811223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg (max 5mg/dose) plus MgO for 1 week
Number of subjects: 84
Study 11811223 — intervention group
Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) alone for 1 week
Number of subjects: 84
Study 30745518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosravuconazole (100 mg, orally once a day for 12 weeks)
Number of subjects: 0
Study 30745518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29652237 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet replacement surgery with the ACADIA facet replacement system
Number of subjects: 2
Study 29652237 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision to titanium posterior spinal fusion and interbody fusion
Number of subjects: 2
Study 26209166 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol at 0.75 μg/day and alendronate at 35 mg/week
Number of subjects: 50
Study 26209166 — intervention group
Group type: COMPARATOR
Intervention: Alendronate at 35 mg/week
Number of subjects: 50
Study 25385669 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal insert (PVI)
Number of subjects: 0
Study 25385669 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone in oil (PIO)
Number of subjects: 0
Study 25385669 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient preference
Number of subjects: 0
Study 25385669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing pregnancy rates
Number of subjects: 0
Study 22237871 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% whey whole protein (50% WWP)
Number of subjects: 13
Study 22237871 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% whey partially hydrolyzed protein (100% WPHP)
Number of subjects: 13
Study 22237871 — intervention group
Group type: COMPARATOR
Intervention: Casein-based formula
Number of subjects: 13
Study 20843369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Personalised Decision Support (PDS)
Number of subjects: 3240
Study 20843369 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tailored Personalised Decision Support (PDS)
Number of subjects: 3240
Study 20843369 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (non-tailored paper-based approach)
Number of subjects: 3240
Study 20843369 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PDS and usual practice)
Number of subjects: 3240
Study 16905564 — intervention group
Group type: COMPARATOR
Intervention: Conventional spacer
Number of subjects: 400
Study 16905564 — intervention group
Group type: COMPARATOR
Intervention: Bottle spacer
Number of subjects: 400
Study 16319891 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (long-acting bronchodilator)
Number of subjects: 0
Study 16319891 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (short-acting beta2-agonist bronchodilator)
Number of subjects: 0
Study 12487223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg orally daily for 1 week
Number of subjects: 20
Study 12487223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9470169 — intervention group
Group type: EXPERIMENTAL
Intervention: M diet (modified milk fat with 16% of cholesterolemic saturated fatty acid replaced by mainly oleic and stearic acids)
Number of subjects: 18
Study 9470169 — intervention group
Group type: COMPARATOR
Intervention: D diet (conventional Danish milk fat)
Number of subjects: 18
Study 9470169 — intervention group
Group type: EXPERIMENTAL
Intervention: M diet
Number of subjects: 18
Study 9470169 — intervention group
Group type: COMPARATOR
Intervention: D diet
Number of subjects: 18
Study 7628834 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) with food intake
Number of subjects: 12
Study 7628834 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) without food intake
Number of subjects: 12
Study 7628834 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem sustained-release (Mono-Tildiem LP 300 mg) at different times of administration
Number of subjects: 12
Study 2689181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine therapy
Number of subjects: 10
Study 926022 — intervention group
Group type: EXPERIMENTAL
Intervention: Target stimuli (finger stimuli)
Number of subjects: 0
Study 926022 — intervention group
Group type: COMPARATOR
Intervention: Random four-finger experiments at a slower rate
Number of subjects: 0
Study 926022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisensory paradigm with finger shocks and acoustic clicks
Number of subjects: 0
Study 29631457 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 11
Study 29631457 — intervention group
Group type: COMPARATOR
Intervention: Without Kinesio taping
Number of subjects: 11
Study 29631457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28559255 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAB5553A (120 mg)
Number of subjects: 26